ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
-3.61%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$6.41B
AUM Growth
+$6.41B
(-9.4%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-2.77%
Top 10 Holdings %
Top 10 Hldgs %
73.95%
Holding
40
New
1
Increased
13
Reduced
7
Closed
7
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$236M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$58.2M |
| 3 |
Merus
MRUS
|
$36.8M |
| 4 |
Kymera Therapeutics
KYMR
|
$35.9M |
| 5 |
Krystal Biotech
KRYS
|
$18.4M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$320M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$96.1M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$30.1M |
| 4 |
United Therapeutics
UTHR
|
$26.3M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$25.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $825M | 12.87% | 2,675,000 -85,300 | -3% | -$26.3M |
|
2
Ascendis Pharma
ASND
$11.8B
| $813M | 12.69% | 5,218,000 +114,945 | +2% | +$17.9M |
|
3
argenx
ARGX
$43.6B
| $731M | 11.41% | 1,235,177 -3,290 | -0.3% | -$1.95M |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $670M | 10.46% | 2,022,222 -6,778 | -0.3% | -$2.25M |
|
|
5
Krystal Biotech
KRYS
$4.27B
| $492M | 7.69% | 2,731,000 +102,178 | +4% | +$18.4M |
|
|
BPMC
6
DELISTED
Blueprint Medicines
BPMC
| $341M | 5.32% | 3,850,000 +2,665,000 | +225% | +$236M |
|
7
Apellis Pharmaceuticals
APLS
$3.48B
| $267M | 4.17% | 12,222,222 | – | – |
|
8
Avidity Biosciences
RNA
$5.99B
| $225M | 3.51% | 7,625,000 +125,000 | +2% | +$3.69M |
|
9
Xenon Pharmaceuticals
XENE
$2.98B
| $193M | 3.01% | 5,741,666 +75,000 | +1% | +$2.52M |
|
10
Soleno Therapeutics
SLNO
$3.6B
| $180M | 2.82% | 2,525,000 | – | – |
|
|
11
Kymera Therapeutics
KYMR
$2.95B
| $177M | 2.76% | 6,460,000 +1,310,000 | +25% | +$35.9M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $171M | 2.66% | 2,674,835 +119,280 | +5% | +$7.61M |
|
13
Amicus Therapeutics
FOLD
$2.34B
| $167M | 2.61% | 20,500,000 -2,675,000 | -12% | -$21.8M |
|
14
Arrowhead Research
ARWR
$3.05B
| $142M | 2.21% | 11,111,111 | – | – |
|
15
Vera Therapeutics
VERA
$1.38B
| $137M | 2.14% | 5,701,900 +91,900 | +2% | +$2.21M |
|
|
16
Merus
MRUS
$4.98B
| $126M | 1.97% | 3,000,000 +875,000 | +41% | +$36.8M |
|
17
MoonLake Immunotherapeutics
MLTX
$3.54B
| $108M | 1.69% | 2,770,100 | – | – |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $82.5M | 1.29% | 625,000 -2,425,000 | -80% | -$320M |
|
19
Alkermes
ALKS
$4.78B
| $80.9M | 1.26% | 2,450,000 | – | – |
|
20
BioCryst Pharmaceuticals
BCRX
$1.74B
| $65.3M | 1.02% | 8,700,000 -3,165,000 | -27% | -$23.7M |
|
21
Ocular Therapeutix
OCUL
$2.12B
| $59.1M | 0.92% | 8,060,000 | – | – |
|
|
CNTA
22
Centessa Pharmaceuticals
CNTA
$2.25B
| $58.2M | 0.91% | +4,050,000 | New | +$58.2M |
|
23
89bio
ETNB
$1.34B
| $46.2M | 0.72% | 6,350,000 +2,250,000 | +55% | +$16.4M |
|
24
MannKind Corp
MNKD
$1.41B
| $44M | 0.69% | 8,750,000 | – | – |
|
25
Vaxcyte
PCVX
$4B
| $37.8M | 0.59% | 1,000,000 -175,000 | -15% | -$6.61M |
|